Company / Free Cash Flow
Fulcrum Therapeutics, Inc. Free Cash Flow History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$60.4M
FY2025
5-year range
-$99.0M / -$2.5M
FY2021-FY2025
Trend
-2319.0%
vs FY2024
Sector context
#84 of 194
Health Care
What the data says
Free Cash Flow changed -2319% YoY in FY2025, a notable deviation from the 7-year average annual change of -335%.
Based on SEC 10-K filings.
-$60M in FY2025.
Improved from -$91M to -$60M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#84 of 194 in Health CareTop 43% of 194This company -$60.4M Sector average $470.6M
▼
-112.8% below sector average
Key checks
Key Insights
- In FY2025, free cash flow decreased 2319.0% year-over-year.
- Ranks #84 out of 194 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2024.
- Lowest free cash flow in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 8.44 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$60.4M | -2319.0% |
| FY2024 | -$2.5M | +97.3% |
| FY2023 | -$91.5M | +7.6% |
| FY2022 | -$99.0M | -23.5% |
| FY2021 | -$80.2M | -45.8% |
| FY2020 | -$55.0M | -36.3% |
| FY2019 | -$40.3M | -27.9% |
| FY2018 | -$31.5M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026